Global Prostate Cancer Diagnostics Market - 2022-2029

Market Overview

Prostate Cancer Diagnostics Market size was valued US$ 5.9 billion in 2021 and is estimated to reach US$ 8.4 billion by 2029, growing at a CAGR of 13.5% during the forecast period (2022-2029).

Prostate cancer begins when cells in the prostate gland start to grow out of control. The prostate is a gland found only in males. It makes some of the fluid that is part of semen.

Almost all prostate cancers are adenocarcinomas. These cancers develop from the gland cells (the cells that make the prostate fluid added to the semen). Some other types of cancer that can start in the prostate include small cell carcinomas, neuroendocrine tumors, transitional cell carcinomas, and sarcomas. Prostate cancer can often be found early by testing prostate-specific antigen (PSA) levels in a man's blood or digital rectal exam (DRE). According to a study in the United States, the annual screening with PSA and DRE did detect more prostate cancers than in men not screened, but this screening did not lower prostate cancer's death rate.

Market Dynamics

The rising R&D initiatives in the prostate cancer diagnostic field and the recent regulatory approvals are driving the growth of the market.

Increasing advancements in diagnostic tests and rising government initiatives for cancer awareness are expected to drive market growth.

The continuous advancements in diagnostic for prostate cancer are driving the growth of the market globally. Some of the new test-launched by major players are:

In mar 2022, U.S.FDA approves Lu-PSMA-617 manufactured by Novartis. It is a radiopharmaceutical therapy that treats prostate cancer.

In Aug 2020, Garnet Health Medical Centre, offered an innovative technology that increases the ability that helps in early diagnosis and treatment of prostate cancer.

On December 29th, 2019, Anixa Biosciences, Inc. commercially launched the Cchek Prostate Cancer Confirmation test (Cchek PCC)- which utilizes artificial intelligence (AI), flow cytometry, and liquid-biopsy technology to detect prostate cancer was commercially launched. Once it becomes available, this test will reduce the need for expensive and invasive biopsy procedures to diagnose prostate cancer patients in certain patients.

In September 2019, a new and simple blood test was found to efficiently and accurately detect the presence of aggressive prostate cancer, according to research by Queen Mary University of London. In combination with the current prostate-specific antigen (PSA) test, the new test could help men avoid unnecessary and invasive biopsies, over-diagnosis and over-treatment. The new prostate cancer test (the Parsortix system from ANGLE plc) detects early cancer cells or circulating tumor cells (CTCs) that have left the original tumor and entered the bloodstream before spreading around the body. In July 2019, MDNA Life Sciences launched the Mitomic Prostate Test (MPTTM), the world's most accurate blood test, to determine whether a man does or does not have prostate cancer that requires treatment (clinically significant prostate cancer1).

High cost associated with diagnostic procedures is expected to hamper the market growth.

The prostate cancer diagnostic methods are very costly and cancer is an asymptomatic disorder that needs proper diagnosis in initial phase. Unaffordable diagnosis and Inaccuracy are likely to hamper the global market.

Industry Analysis

The global prostate cancer diagnostics market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Technology Advancement.

Segment Analysis

Prostate-specific antigen (PSA) test segment is expected to hold the largest market share in global prostate cancer diagnostics market

Prostate-specific Antigen (PSA) is a protein produced by prostate cells, and the PSA test is performed to diagnose prostate cancer (PCa) in men and for follow-up post-treatment to check if cancer relapses. PSA testing is an essential tool for detecting prostate cancer, which measures PSA's level in a man's blood. Medicare and several private insurers provide coverage for an annual PSA test for all Medicare-eligible men aged 50 and older. PSA testing is gaining popularity among clinicians and hospitals, owing to the increasing number of people affected by prostate cancer. It has more market value in the countries with a high prevalence rate (Western) and low prevalence rate (Asian), as PSA is used globally for the early detection/screening of prostate cancer. The major players continuously innovate new PSA with advanced technology, which boosts the PSA test's growth in the prostate cancer diagnosis market. For instance, in February 2019, OPKO Health, Inc. received the U.S. Food and Drug Administration (FDA) approval for the point-of-care Sangia Total Prostate Specific Antigen (PSA) Test using the Claros 1 Analyzer. The product is indicated to quantitatively measure total PSA in whole blood from a fingerstick of blood collected by a healthcare professional. It is used in conjunction with a digital rectal exam to detect prostate cancer in men aged 50 years and older.

Geographical Analysis

North America region holds the largest market share in the global prostate cancer diagnostics market

North America is dominating the global prostate cancer diagnostics market, with the United States accounting as the major contributor to the market. Prostate cancer is one of the most common cancers in American men, and this is made apparent by the statistics surrounding it. It affects 1 out of eight men in U.S. After skin cancer it is the most common cancer in U.S. men. American Cancer Society estimated that in 2022 around 268,490 novel cases of prostate cancer will be detected. Some of the prostate cancers are aggressive but most of them grows slowly. The number of deaths increases year after year, making prostate cancer the second leading cause of cancer death in men in the United States. Hence, it is considered to have an early diagnosis of the condition.

The United States Preventive Services Task Force has analyzed the data from all reported prostate cancer screening trials, principally from the PLCO and ERSPC trials, and estimated that every 1,000 men ages 55 to 69 years screened every 1 to 4 years for 10 to 15 years. About 1 death from prostate cancer can be avoided. 120 men would have a false-positive test result that leads to a biopsy, and some men who get a biopsy would experience at least moderately bothersome symptoms from the biopsy. 100 men would be diagnosed with prostate cancer. Of those, 80 would be treated (either immediately or after a period of active surveillance) with surgery or radiation. At least 60 of these men would have a serious complication from treatment, such as erectile dysfunction and/or urinary incontinence.

Competitive Landscape

The growing awareness towards the availability of advanced cancer diagnostics technologies, especially in the emerging regions, is also likely to grow the prostate cancer diagnostics market. In addition to this, various governments' supportive initiatives across the globe would help boost the market growth.

Some of the major players dominating the market include Genomic Health, Inc., Quanterix Corporation, Metamark Genetics, Myriad Genetics, Inc., MDx Health, Siemens Healthcare GmbH, F. Hoffman-La Roche AG, OPKO Health, Inc., among others.

The key players are adopting several strategies such as product launches, partnerships, mergers and acquisitions, collaborations, finding a new market in their core competency to stay competitive in the market.

For instance,

• In June 2019, OPKO Health, Inc. (had submitted a de novo request to the U.S. Food and Drug Administration (FDA) seeking regulatory clearance for the 4Kscore test. The 4Kscore test is a blood test used by health care professionals to assess a patient's risk of having aggressive prostate cancer after an abnormal prostate-specific antigen (PSA) test result and before a decision is made to perform a biopsy.
• In July 2019, MDNA Life Sciences launched the Mitomic Prostate Test (MPT) in the UK, the world's most accurate blood test to determine whether a man does or does not have prostate cancer that requires treatment.

Key Companies to Watch

Myriad Genetics:

Overview: Myriad Genetics, Inc. is American company that works in precision medicine and genetic testing. It was founded in 1991 and is headquartered in Utah, United States. It uses various proprietary technologies that helps doctors and patients understand the disease on the basis of genetics of human and gene role in treatment. With the help of this data and information new products are manufactured.

Product Portfolio:

Prolaris: It analyses the functional activity of genes that are involved in cancer cell proliferation and anticipates the cancer aggressiveness with the help of tissues that are collected during biopsy to confirm cancer diagnosis.

Key Developments: In Mar 2022, Myriad Genetics BRAC Analysis CDx test received FDA approval. It is used as an aid diagnostic that determine BRCA mutated variant.

The global prostate cancer diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.